TD Cowen reiterated a Buy rating for Boston Scientific (NYSE:BSX) stock, maintaining a price target of $110.00. The stock, currently trading at $98.78, has shown remarkable momentum, reaching new ...
The most recent trading session ended with Boston Scientific (BSX) standing at $98.66, reflecting a +0.5% shift from the previouse trading day's closing. The stock lagged the S&P 500's daily gain of 1 ...
The FDA said the use of the affected products may also cause stomach ... the health regulator added. On Oct. 10, Boston Scientific sent an urgent medical device advisory to all affected customers ...
At the J.P. Morgan Healthcare Conference, Boston Scientific forecast that pulsed field ablation will be used in more than 60% of atrial fibrillation procedures globally by 2026.
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.
Beyond technological innovations and effectiveness, a key factor is its cost-reduction approach to its products, enabling greater adoption by the medical community. Boston Scientific has performed ...
Patients already treated don’t need to do anything. Boston Scientific has updated its instructions for doctors using catheter technology to treat atrial fibrillation with extreme cooling ...
Boston Scientific (BSX) ended the recent trading ... account the stock's expected earnings growth rate. The Medical - Products was holding an average PEG ratio of 2.58 at yesterday's closing ...